195 Evaluation of Various Treatment Strategies for Acquired Hemophilia A

Introduction: Acquired hemophilia A (AHA) is a rare bleeding disorder caused by formation of autoantibodies against factor VIII. Patients with AHA typically present with a prolonged activated partial thromboplastin, bruising, or bleeding. It is associated with a high morbidity and mortality rate if not managed promptly. Strategies for hemostasis include surgical management, bypassing agents, anti-fibrinolytics, desmopressin or exogenous factor replacement (recombinant or plasma-derived human FVIII concentrates or recombinant porcine factor III).